Bempedoic acid (original) (raw)
Bempedoinsäure ist ein Arzneistoff, der zur Senkung des LDL-Cholesterins bei Erwachsenen mit bestimmten Fettstoffwechselstörung eingesetzt wird. Als Inhibitor der Adenosintriphosphat-Citrat-Lyase (ACL) senkt Bempedoinsäure das LDL-Cholesterin durch Hemmung der Cholesterinsynthese.
| Property | Value |
|---|---|
| dbo:abstract | L'àcid bempedoic, comercialitzat com a Nexletol o Nustendi, és un fàrmac per al tractament de l'hipercolesterolèmia (nivells de colesterol de sang elevats). Els efectes secundaris més comuns inclouen hiperuricèmia (nivells elevats d'àcid úric en sang), dolor a les extremitats, i anèmia (baix recompte d'eritròcits). L'àcid bempedoic bloqueja un enzim hepàtic, l'adenosintrifosfat-citrat-liasa, involucrat en la síntesi del colesterol. L'àcid va ser aprovat per al seu ús en humans als Estats Units al febrer del 2020, i a la Unió Europea a l'abril del 2020. La U.S. Food and Drug Administration (FDA) el considera el primer fàrmac de la seva classe. (ca) Bempedoic acid, sold under the brand name Nexletol among others, is a medication for the treatment of hypercholesterolemia (high blood cholesterol levels). The most common side effects include hyperuricemia (high blood levels of uric acid), pain in arms or legs, and anemia (low red blood cell counts). Bempedoic acid blocks an enzyme in the liver called adenosine triphosphate-citrate lyase, which is involved in making cholesterol. Bempedoic acid was approved for use in the United States in February 2020, and for use in the European Union in April 2020. The U.S. Food and Drug Administration (FDA) considers it to be a first-in-class medication. (en) Bempedoinsäure ist ein Arzneistoff, der zur Senkung des LDL-Cholesterins bei Erwachsenen mit bestimmten Fettstoffwechselstörung eingesetzt wird. Als Inhibitor der Adenosintriphosphat-Citrat-Lyase (ACL) senkt Bempedoinsäure das LDL-Cholesterin durch Hemmung der Cholesterinsynthese. (de) L'acide bempédoïque est une molécule inhibitrice de l'ATP citrate lyase utilisé dans le traitement de l'hypercholestérolémie. (fr) |
| dbo:alternativeName | Nexletol, Nilemdo (en) |
| dbo:casNumber | 738606-46-7 |
| dbo:chEBI | 149601 |
| dbo:chEMBL | 3545313 |
| dbo:drugbank | DB11936 |
| dbo:fdaUniiCode | 1EJ6Z6Q368 |
| dbo:kegg | D10691 |
| dbo:medlinePlus | a620020 |
| dbo:pubchem | 10472693 |
| dbo:thumbnail | wiki-commons:Special:FilePath/Bempedoic_acid.svg?width=300 |
| dbo:wikiPageExternalLink | https://druginfo.nlm.nih.gov/drugportal/name/bempedoic%20acid |
| dbo:wikiPageID | 60227276 (xsd:integer) |
| dbo:wikiPageLength | 16442 (xsd:nonNegativeInteger) |
| dbo:wikiPageRevisionID | 1119660819 (xsd:integer) |
| dbo:wikiPageWikiLink | dbr:Pravastatin dbr:Mortality_rate dbr:Metabolite dbr:Bempedoic_acid/ezetimibe dbr:Area_under_the_curve_(pharmacokinetics) dbr:Cytochrome_P450 dbr:Uric_acid dbr:Limb_(anatomy) dbc:Dicarboxylic_acids dbr:Oral_administration dbr:Thioester dbr:SLC22A7 dbr:Coenzyme_A dbr:Gout dbr:Morbidity dbr:Anemia dbr:Simvastatin dbr:Statin dbr:Committee_for_Medicinal_Products_for_Human_Use dbr:Gastrointestinal dbr:Prodrug dbr:HMG-CoA_reductase dbr:SLCO1B1 dbr:Aldo-keto_reductase dbr:Esperion_Therapeutics dbr:Ezetimibe dbr:Familial_hypercholesterolemia dbr:Food_and_Drug_Administration dbr:Carboxylic_acid dbr:Cardiovascular_disease dbr:Glucuronidation dbr:Rotator_cuff dbc:Hypolipidemic_agents dbr:ATP_citrate_lyase dbr:Heterozygous dbr:Adenosine_triphosphate-citrate_lyase dbr:Hypercholesterolemia dbr:Hyperuricemia dbr:AMP-activated_protein_kinase dbr:Achilles_tendon dbr:Cholesterol dbr:Biological_half-life dbr:Placebo dbr:First-in-class_medication dbr:SLC27A2 dbr:SLCO1B3 dbr:Tendon_rupture dbr:LDL_cholesterol dbr:Atherosclerotic dbr:Biceps_tendon dbr:Fixed-dose_combination dbr:Muscle_spasm dbr:Plasma_protein dbr:File:Bempedoyl-CoA.svg dbr:File:ESP15228_skeletal.svg |
| dbp:atcPrefix | 10.0 |
| dbp:atcSuffix | AX15 (en) |
| dbp:c | 19 (xsd:integer) |
| dbp:casNumber | 738606 (xsd:integer) |
| dbp:chebi | 149601 (xsd:integer) |
| dbp:chembl | 3545313 (xsd:integer) |
| dbp:chemspiderid | 8648104 (xsd:integer) |
| dbp:dailymedid | Nexletol (en) |
| dbp:drugbank | DB11936 (en) |
| dbp:eliminationHalfLife | 39600.0 |
| dbp:excretion | 70 (xsd:integer) |
| dbp:h | 36 (xsd:integer) |
| dbp:iupacName | 8 (xsd:integer) |
| dbp:iupharLigand | 8321 (xsd:integer) |
| dbp:kegg | D10691 (en) |
| dbp:legalEu | Rx-only (en) |
| dbp:legalStatus | Rx-only (en) |
| dbp:legalUk | POM (en) |
| dbp:legalUs | Rx-only (en) |
| dbp:licenceEu | yes (en) |
| dbp:medlineplus | a620020 (en) |
| dbp:metabolism | dbr:Glucuronidation |
| dbp:o | 5 (xsd:integer) |
| dbp:pregnancyCategory | Contraindicated (en) |
| dbp:proteinBound | 99.3 |
| dbp:pubchem | 10472693 (xsd:integer) |
| dbp:routesOfAdministration | dbr:Oral_administration |
| dbp:smiles | CCCO (en) |
| dbp:stdinchi | 1 (xsd:integer) |
| dbp:stdinchikey | HYHMLYSLQUKXKP-UHFFFAOYSA-N (en) |
| dbp:synonyms | ESP-55016, ETC-1002 (en) |
| dbp:tradename | Nexletol, Nilemdo (en) |
| dbp:unii | 1 (xsd:integer) |
| dbp:wikiPageUsesTemplate | dbt:As_of dbt:Cite_journal dbt:Cite_web dbt:Infobox_drug dbt:Portal_bar dbt:Reflist dbt:Use_dmy_dates dbt:Drugs.com dbt:ClinicalTrialsGov dbt:Lipid_modifying_agents |
| dcterms:subject | dbc:Dicarboxylic_acids dbc:Hypolipidemic_agents |
| rdf:type | owl:Thing dul:ChemicalObject dbo:ChemicalSubstance wikidata:Q8386 dbo:Drug |
| rdfs:comment | Bempedoinsäure ist ein Arzneistoff, der zur Senkung des LDL-Cholesterins bei Erwachsenen mit bestimmten Fettstoffwechselstörung eingesetzt wird. Als Inhibitor der Adenosintriphosphat-Citrat-Lyase (ACL) senkt Bempedoinsäure das LDL-Cholesterin durch Hemmung der Cholesterinsynthese. (de) L'acide bempédoïque est une molécule inhibitrice de l'ATP citrate lyase utilisé dans le traitement de l'hypercholestérolémie. (fr) L'àcid bempedoic, comercialitzat com a Nexletol o Nustendi, és un fàrmac per al tractament de l'hipercolesterolèmia (nivells de colesterol de sang elevats). Els efectes secundaris més comuns inclouen hiperuricèmia (nivells elevats d'àcid úric en sang), dolor a les extremitats, i anèmia (baix recompte d'eritròcits). (ca) Bempedoic acid, sold under the brand name Nexletol among others, is a medication for the treatment of hypercholesterolemia (high blood cholesterol levels). The most common side effects include hyperuricemia (high blood levels of uric acid), pain in arms or legs, and anemia (low red blood cell counts). Bempedoic acid blocks an enzyme in the liver called adenosine triphosphate-citrate lyase, which is involved in making cholesterol. (en) |
| rdfs:label | Bempedoic acid (en) Àcid bempedoic (ca) Bempedoinsäure (de) Acide bempédoïque (fr) |
| owl:sameAs | wikidata:Bempedoic acid dbpedia-ca:Bempedoic acid dbpedia-de:Bempedoic acid dbpedia-fr:Bempedoic acid http://or.dbpedia.org/resource/ବେମ୍ପେଡୋଇକ_ଏସିଡ dbpedia-vi:Bempedoic acid https://global.dbpedia.org/id/2Y19f |
| prov:wasDerivedFrom | wikipedia-en:Bempedoic_acid?oldid=1119660819&ns=0 |
| foaf:depiction | wiki-commons:Special:FilePath/Bempedoic_acid.svg wiki-commons:Special:FilePath/Bempedoyl-CoA.svg wiki-commons:Special:FilePath/ESP15228_skeletal.svg |
| foaf:isPrimaryTopicOf | wikipedia-en:Bempedoic_acid |
| is dbo:wikiPageRedirects of | dbr:C19H36O5 dbr:Nexletol dbr:Nilemdo |
| is dbo:wikiPageWikiLink of | dbr:Bempedoic_acid/ezetimibe dbr:C19H36O5 dbr:Lipid-lowering_agent dbr:Daiichi_Sankyo dbr:Esperion_Therapeutics dbr:ATC_code_C10 dbr:ATP_citrate_synthase dbr:First-in-class_medication dbr:Nexletol dbr:Nilemdo |
| is foaf:primaryTopic of | wikipedia-en:Bempedoic_acid |
